Development of quorum-sensing inhibitors, antimicrobial peptides and mimics, and incorporating them into polymers and biomaterials with the aim of reducing device-related infections.
- Portfolio of antimicrobial and antibiofilm agents and scaffolds with novel mechanisms of action
- Antimicrobial coatings technologies with demonstrated in-vivo efficacy at preventing device-related infections
- Recognised international experts in the field of antimicrobial discovery and biomaterials
- Outstanding track record in the area of novel surface strategies for antimicrobial control with multiple industry-supported and government funding in this area
Up to 65% of all hospital acquired infections are caused by microbial colonisation of surfaces. This is a major health problem that can be prevented by new technologies which will save billions of dollars in healthcare costs and provide substantial economic benefits for industries.
- Completed Phase1/Phase III clinical trials for antimicrobial contact lenses
- Antimicrobial prototype devices for major biomedical companies including Cochlear
Capabilities and facilities
- World class synthetic chemistry facilities including NMR and mass spectrometry, supported by a diverse range of imaging and surface characterisation facilities from the Mark Wainwright Analytical Centre
- Clinically relevant animal models for device-related infections
- Blogisnal Ltd
- Cochlear Ltd
- Australian Biotechnologies Pty Ltd
- Intellectual Ventures (now Xinova)
- Allegra Orthopaedics